Synthetic method of rosaxostat
By employing steps such as free radical substitution, addition, coupling, alkaline hydrolysis, and amine ester exchange, the problems of isomer separation, long reaction time, and expensive reagents in the synthesis of roxadustat have been solved, enabling efficient and low-cost industrial production.
Patent Information
- Application Number
- CN202411292701.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-29
AI Technical Summary
Existing synthetic routes for roxadustat suffer from problems such as difficulty in isomer separation, long reaction times, use of easily manufactured toxins and expensive reagents, and unsuitability for industrial production.
The process employs steps such as free radical substitution, addition, coupling, alkaline hydrolysis, methylation, and amino ester exchange, using inexpensive and readily available raw materials and mild reaction conditions, reducing the use of toxic reagents and simplifying the process route.
A method for synthesizing roxadustat with a short process route, simple operation, high overall yield, and low cost has been developed, making it suitable for industrial production.
Smart Images

Figure BDA0005045079370000011 
Figure BDA0005045079370000021 
Figure BDA0005045079370000031
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of chemical engineering and chemical medicine, and more specifically, to a method for synthesizing roxadustat. Background Art
[0002] Roxadustat is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) originally developed by FibroGen. In December 2018, the National Medical Products Administration approved the marketing of roxadustat capsules for the treatment of anemia symptoms in patients with chronic kidney disease or myelodysplastic syndrome. The trade name is Adroit.
[0003] Roxadustat mimics 2-oxoglutarate, the substrate of PHD, and inhibits PHD by competitive binding, stabilizing HIF-α levels under normoxic conditions, thereby upregulating endogenous EPO and improving anemia symptoms. China was the first to complete the Phase III clinical trial of roxadustat, and it was approved for marketing in 2018 for the treatment of CKD and anemia. The Chinese clinical trial FGCL-4592-806 verified that roxadustat is not inferior to epoetin alfa in the treatment of patients with dialysis (including HD, PD) and anemia, that is, after 23 to 27 weeks of treatment, the average Hb baseline value in the roxadustat group increased by (7±11) g / L, while that in the epoetin alfa group increased by (5±10) g / L. In addition, compared with epoetin alfa, roxadustat can more effectively increase transferrin levels, maintain serum iron levels, and reduce the decline in transferrin saturation.
[0004] The chemical name of roxadustat is (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine; its English name is (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine; molecular formula: C 19 H 16 N2O5; molecular weight: 352.11; CAS number: 808118-40-3.
[0005]
[0006] The synthetic route of roxadustat in the prior art is as follows:
[0007] Route 1: The prior art of WO2013013609 discloses a method for synthesizing rosuvastatin. The process route is as follows. The method uses 4-nitrophthalonitrile (intermediate A-1) as the starting material and reacts with phenol to undergo an aromatic nucleophilic substitution reaction. Intermediate A-2 is refluxed in a methanol aqueous solution of sodium hydroxide for 48 hours to hydrolyze the cyano group to obtain intermediate A-3. Intermediate A-3 is refluxed with acetic anhydride in an acetic acid solvent to generate intermediate A-4. A-4 reacts with methyl isocyanate to obtain intermediate A-5. At 60°C, concentrated hydrochloric acid is added to the methanol solvent of intermediate A-5 and reacted for 4 hours. Then, it is separated by chromatography to obtain intermediate A-6. Intermediate A-6 is reacted in POCl3 to obtain intermediate A-7. It is then reacted with trimethyl boron under the catalysis of Pd(PPh3)4 to obtain intermediate A-8. A-8 is hydrolyzed to obtain A-9. Then, intermediate A-9 is reacted with glycine methyl ester hydrochloride to obtain intermediate A-10. Finally, it is hydrolyzed in an ethanol aqueous solution of sodium hydroxide to obtain roxadustat.
[0008] This route will produce isomers when constructing the isoquinoline ring, which requires column chromatography separation, which is difficult; the reaction time is too long in the synthesis of A-2, A-3, etc. From the reagents used, the acetic anhydride used in the middle is a drug-making and controlled reagent; the trimethylborane and Pd(PPh3)4 used are too expensive and not suitable for large-scale industrial production.
[0009]
[0010] Route 2: The prior art of WO2021252295 A discloses a method for synthesizing rosuvastatin. The process route is as follows: first, 4-phenoxybenzaldehyde (B-1) is used as a starting material and reacted with intermediate B-2 to obtain intermediate B-3. B-3 is reduced under the action of hydrogen using ethanol as a solvent and Rh(Rc,Sp-Duanphos)(NBD)BF4 as a catalyst to obtain intermediate B-4. Intermediate B-4 is reacted with phosgene and ferric chloride at room temperature using dichloromethane as a solvent, and is separated and purified by column chromatography to obtain intermediate B-5. Concentrated sulfuric acid is added to intermediate B-5 in an ethanol solvent, refluxed overnight for reaction, and separated by column chromatography to obtain intermediate B-6. Then, intermediate B-7 is obtained by catalytic hydrogenation. B-7 reacts with p-toluenesulfonyl chloride to obtain intermediate B-8. Intermediate B-8 is added with ammonium cerium nitrate in an acetonitrile aqueous solution for 3 hours, and purified by column chromatography to obtain intermediate B-9. Then, phenol was added to a 33% hydrobromic acid-acetic acid solution and reacted at room temperature to obtain intermediate B-10. Then, the intermediate was dissolved in a sodium methoxide-methanol solution in a pressure-resistant container and reacted with glycine to obtain rosuvastatin.
[0011] The starting materials of this route are relatively expensive, and many expensive catalysts and reagents are used. In addition, substances such as phosgene and hydrobromic acid are highly toxic. Some reactions are dangerous, for example, hydrogen is used in the reduction of intermediate B-6, and a pressure-resistant container is used in the synthesis of rosuvastatin. In the post-reaction treatment process, column chromatography is used for separation and purification in the synthesis of B-5, B-6, etc. Taking all factors into consideration, this route is not suitable for large-scale industrial production.
[0012]
[0013] Route 3: US10118897 B in 2014 disclosed a synthetic route using 5-bromophthalide (C-1) as the starting material. The process route is as follows: First, C-1 reacts with phenol to generate intermediate C-2. Then, toluene is used as a solvent, and SOCl2, trimethyl borate, and dichlorotriphenylphosphine are used to reflux with it, and then reacted with methanol to generate intermediate C-3. C-3 reacts with p-toluenesulfonylglycine methyl ester to obtain C-4, and then Claisen ester condensation is carried out in sodium methoxide-methanol solution to construct an isoquinoline ring to obtain C-5. Then, it reacts with tetramethylmethanediamine at 55°C to obtain intermediate C-6, and then at 100°C, under the action of acetic anhydride, acetoxymethyl is generated at the C-1 position of the isoquinoline ring, hydroxyethyl is esterified, and then reacts with morpholine to generate intermediate C-7. C-7 is catalytically hydrogenated to obtain intermediate A-10. A-10 then reacts with glycine in a sodium methoxide-methanol solution to generate rosuvastatin.
[0014] This route uses expensive dichlorotriphenylphosphine, and industrial production will greatly increase costs; regulated acetic anhydride is used in the methylation process at the C-1 position of the isoquinoline ring, and H2 / Pd is used in the deacetoxy process, which will increase special equipment and production costs.
[0015]
[0016] Route 4: The prior art of CN104892509 B discloses a synthetic route using L-tyrosine (D-1) as the starting material. The process route is shown below. First, the starting material is subjected to an esterification reaction to obtain an intermediate D-2. D-2 is then refluxed with potassium methoxide in methanol, the solvent is removed, and the resulting residue is reacted with bromobenzene to obtain an intermediate D-3. D-3 is refluxed with acetaldehyde and concentrated hydrochloric acid for 6 hours, and cyclized to produce an intermediate D-4. D-4 reacts with p-toluenesulfonyl chloride at room temperature to produce D-5. Thereafter, hydrogen peroxide and p-toluenesulfonyl chloride are used to react for 40 hours, and hydroxylation is performed to obtain an intermediate A-10. A-10 is subjected to an amine ester exchange with glycine at 120°C in a pressure-resistant container using sodium methoxide as a base to obtain the final product, rosuvastatin.
[0017] This route involves high-temperature reactions in the process of synthesizing D-3, and a pressure-resistant container is used in the last step; in the process of synthesizing the intermediate D-3, the product of the reaction between bromobenzene and amino groups is produced, which increases the by-products.
[0018]
[0019] Route 5: The prior art of CN107954931B discloses a relatively simple method for methylation of the C-1 position of the isoquinoline ring, and the process route is as follows. Using 4-hydroxy-7-phenoxyisoquinoline-3-carboxylic acid methyl ester (E1) as the starting material and 1,3-dibromo-5,5-dimethylhydantoin as the bromination reagent, the intermediate E-2 is obtained by reflux in a methanol solution for 6 hours. Then, it reacts with methylboric acid under the catalysis of Pd(PPh3)4 to obtain E-3. Then, it is amidated with glycine methyl ester hydrochloride, and then alkaline hydrolysis is performed to obtain rosuvastatin.
[0020] The overall route is shorter, with a yield of 48%, which is relatively high. However, the starting materials are not easy to obtain and are difficult to synthesize, and expensive Pd(PPh3)4 is used, which is not suitable for large-scale industrial production.
[0021]
[0022] In summary, the above routes have the disadvantages of producing isomers, long process routes, expensive and difficult to obtain raw materials, harsh and difficult to control reaction conditions, which leads to high production costs and is not suitable for industrial production. Summary of the invention
[0023] The purpose of the present invention is to overcome the above-mentioned defects of the prior art and provide a method for synthesizing rosuvastatin with a short process route, cheap and readily available raw materials, mild reaction conditions, high total yield, low production cost and suitable for industrial production, while reducing the use of toxic reagents.
[0024] To achieve the above object, the technical solution of the present invention is as follows:
[0025] A method for synthesizing roxadustat, characterized in that it comprises the following steps:
[0026] (1) mixing 5-bromoisobenzofuran-1(3H)-one as shown in formula I with a brominating agent and a free radical initiator in carbon tetrachloride to carry out a free radical substitution reaction to obtain 3,5-dibromoisobenzofuran-1(3H)-one as shown in formula II, and after concentration, adding water to the obtained concentrated product to carry out a hydrolysis reaction to obtain 4-bromo-2-formylbenzoic acid as shown in formula III;
[0027]
[0028] (2) mixing the 4-bromo-2-formylbenzoic acid with methylmagnesium bromide in anhydrous tetrahydrofuran for addition reaction to obtain 5-bromo-3-methylisobenzofuran-1(3H)-one as shown in Formula IV;
[0029]
[0030] (3) mixing the 5-bromo-3-methylisobenzofuran-1(3H)-one with phenol, a catalyst, a ligand and an alkali in N,N-dimethylformamide to react to obtain 3-methyl-5-phenoxyisobenzofuran-1(3H)-one as shown in Formula V;
[0031]
[0032] (4) subjecting the 3-methyl-5-phenoxyisobenzofuran-1(3H)-one to alkaline hydrolysis in an isopropanol aqueous solution to obtain potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate as shown in Formula VI;
[0033]
[0034] (5) mixing the potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate with a methylating agent in an N,N-dimethylformamide solution to carry out a methylation reaction, adding an acid binding agent and a chlorinating agent to the reaction product to continue the reaction, and obtaining methyl 2-(1-chloroethyl)-4-phenoxybenzoate as shown in Formula VII;
[0035]
[0036] (6) mixing the methyl 2-(1-chloroethyl)-4-phenoxybenzoate with an acid-binding agent, a catalyst and methyl p-toluenesulfonylglycine in N,N-dimethylformamide to react to obtain methyl 2-(1-((N-(2-methoxy-2-oxoethyl)-4-methylphenyl)sulfonamido)ethyl)-4-phenoxybenzoate as shown in Formula VIII, and adding sodium methoxide-methanol solution to the reaction product to continue the reaction to obtain methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate as shown in Formula IX;
[0037]
[0038] (7) reacting the 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester with glycine in an acetonitrile solution under a strong base condition to obtain the rosuvastatin.
[0039] Implementing the embodiments of the present invention will have the following beneficial effects:
[0040] The present invention develops a new synthesis method of rosuvastatin, which has the advantages of short process route, simple operation steps, cheap and readily available raw materials, mild reaction conditions, easy control of impurities, high total yield and low production cost. It can be suitable for industrial production and can reduce the use of toxic reagents, which is economical and environmentally friendly. DETAILED DESCRIPTION
[0041] The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited in any way.
[0042] The invention discloses a method for synthesizing roxadustat, comprising the following steps:
[0043] (1) 5-bromoisobenzofuran-1(3H)-one as shown in formula I is mixed with a brominating agent and a free radical initiator in carbon tetrachloride to carry out a free radical substitution reaction to obtain 3,5-dibromoisobenzofuran-1(3H)-one as shown in formula II. After concentration, water is added to the obtained concentrated product to carry out a hydrolysis reaction to obtain 4-bromo-2-formylbenzoic acid as shown in formula III.
[0044] In a specific embodiment, the bromination agent is N-bromosuccinimide (NBS), and the free radical initiator is azobisisobutyronitrile (AIBN).
[0045] In a specific embodiment, the molar ratio of 5-bromoisobenzofuran-1(3H)-one, N-bromosuccinimide and azobisisobutyronitrile is 1:(1.1-2):(0.1-0.2).
[0046] In a specific embodiment, step (1) specifically includes the following steps:
[0047] (1.1) 5-bromoisobenzofuran-1(3H)-one is added to carbon tetrachloride in batches according to a specific ratio, and azobisisobutyronitrile and N-bromosuccinimide are mixed, and a free radical substitution reaction is carried out at 80°C to 90°C for 6h to 7h. After the reaction is completed, the solvent is concentrated and recovered. The amount of carbon tetrachloride used (volume) is 1 / 2 of the amount of 5-bromoisobenzofuran-1(3H)-one used (mass)
[0048] (1.2) Add purified water to the concentrated product and continue the reaction at 90°C to 100°C for 2h to 3h. The amount of purified water (volume) is 1 / 3 of the theoretical yield (mass) of 3,5-bromoisobenzofuran-1(3H)-one.
[0049]
[0050] (2) 4-bromo-2-formylbenzoic acid is mixed with methylmagnesium bromide in anhydrous tetrahydrofuran to carry out an addition reaction to obtain 5-bromo-3-methylisobenzofuran-1(3H)-one as shown in Formula IV.
[0051] In a specific embodiment, the molar ratio of 4-bromo-2-formylbenzoic acid to methylmagnesium bromide is 1:(1-1.1).
[0052] In a specific embodiment, step (2) specifically includes the following steps:
[0053] Under a nitrogen atmosphere, 4-bromo-2-formylbenzoic acid was dissolved in anhydrous THF, mixed with methylmagnesium bromide in a specific ratio, and subjected to addition reaction at -30°C to -20°C for 5h to 6h.
[0054]
[0055] (3) 5-bromo-3-methylisobenzofuran-1(3H)-one is reacted with phenol, a catalyst, a ligand and an alkali in N,N-dimethylformamide to obtain 3-methyl-5-phenoxyisobenzofuran-1(3H)-one as shown in Formula V.
[0056] In a specific embodiment, the added catalyst is cuprous iodide, the alkali is potassium carbonate, the ligand is acetylacetone, and the molar ratio of 5-bromo-3-methylisobenzofuran-1(3H)-one, phenol, potassium carbonate, cuprous iodide, and acetylacetone is 1:(1.5-2):(1.5-2):(0.1-0.2):(0.1-0.2).
[0057] In a specific embodiment, step (3) specifically includes the following steps:
[0058] Under nitrogen atmosphere, 5-bromo-3-methylisobenzofuran-1(3H)-one, phenol, potassium carbonate, acetylacetone, and cuprous iodide are added to DMF in a specific ratio and mixed, and Ullmann coupling reaction is carried out at 100° C. to 120° C. for 8 h to 24 h to obtain 3-methyl-5-phenoxyisobenzofuran-1(3H)-one. Preferably, the Ullmann coupling reaction is carried out at 110° C.
[0059]
[0060] (4) 3-methyl-5-phenoxyisobenzofuran-1(3H)-one is subjected to alkaline hydrolysis reaction in an isopropanol aqueous solution to obtain potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate as shown in formula VI.
[0061] In a specific embodiment, the alkaline hydrolysis is carried out in a potassium hydroxide solution, and the molar ratio of 3-methyl-5-phenoxyisobenzofuran-1(3H)-one to potassium hydroxide is 1:(1.0-1.1).
[0062] In a specific embodiment, step (4) specifically includes the following steps:
[0063] Add 3-methyl-5-phenoxyisobenzofuran-1(3H)-one to an isopropanol aqueous solution (isopropanol: water = 99:1), slowly add solid potassium hydroxide (powder) under stirring, hydrolyze at 40°C to 60°C for 1h to 4h, and filter to obtain the precipitated potassium salt.
[0064]
[0065] (5) Potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate is mixed with a methylating agent in an N,N-dimethylformamide solution to carry out a methylation reaction, and an acid binding agent and a chlorinating agent are added to the reaction product to continue the reaction to obtain methyl 2-(1-chloroethyl)-4-phenoxybenzoate as shown in Formula VII.
[0066] In a specific embodiment, the methylating agent is dimethyl sulfate, the molar ratio of potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate to dimethyl sulfate is 1:(1.0-1.1), the acid binding agent added after the reaction is completed is triethylamine, the chlorinating agent is thionyl chloride, and the molar ratio of potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate, triethylamine and thionyl chloride is 1:(1-2):(1-2).
[0067] In a specific embodiment, step (5) specifically includes the following steps:
[0068] (5.1) Potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate was dissolved in DMF, stirred in an ice-water bath, and dimethyl sulfate was slowly added dropwise according to a specific ratio. The methylation reaction was carried out at 0°C to room temperature for 1 h to 2 h. After the reaction was completed, the next step was carried out without further treatment.
[0069] (5.2) While stirring in an ice bath, slowly drop triethylamine in the correct ratio into the solution, maintain the temperature and stir for 0.5 h, then slowly drop thionyl chloride to allow the halogen substitution reaction to occur at 0°C to room temperature for 2 h to 4 h.
[0070]
[0071] (6) Methyl 2-(1-chloroethyl)-4-phenoxybenzoate is mixed with an acid-binding agent, a catalyst and methyl p-toluenesulfonylglycine in N,N-dimethylformamide to carry out a nucleophilic substitution reaction to obtain methyl 2-(1-((N-(2-methoxy-2-oxoethyl)-4-methylphenyl)sulfonamido)ethyl)-4-phenoxybenzoate as shown in Formula VIII. Sodium methoxide-methanol solution is added to the reaction product for cyclization to obtain methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate as shown in Formula IX.
[0072] In a specific embodiment, the acid binding agent is potassium carbonate, the catalyst is potassium iodide, and the molar ratio of 2-(1-chloroethyl)-4-phenoxybenzoic acid methyl ester, p-toluenesulfonylglycine methyl ester, potassium carbonate, and potassium iodide is 1.0:(1.5-2.0):2.0:0.1.
[0073] In a specific embodiment, step (6) specifically includes the following steps:
[0074] (6.1) Methyl 2-(1-chloroethyl)-4-phenoxybenzoate, methyl p-toluenesulfonylglycine, potassium carbonate and potassium iodide are added to DMF in a specific ratio, and a nucleophilic substitution reaction is carried out at 50°C to 60°C for 2h to 8h. The reaction is carried out to the next step without any post-treatment.
[0075] (6.2) Sodium methoxide-methanol solution is added to the reaction solution, and a cyclization reaction is carried out at 50°C to 70°C for 4h to 7h to obtain 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester.
[0076]
[0077] (7) Methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate is subjected to an amine transesterification reaction with glycine in an acetonitrile solution under strong alkaline conditions to obtain rosuvastatin.
[0078] In a specific embodiment, the base is 1,8-diazacyclo[5,4,0]undecene-7,4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester, glycine, and 1,8-diazacyclo[5,4,0]undecene in a molar ratio of 1:(2-4):(2-3).
[0079] In a specific embodiment, step (7) specifically includes the following steps:
[0080] 4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester, glycine, and 1,8-diazacyclo[5,4,0]undecene are added to acetonitrile in a specific ratio, and an amine ester exchange reaction is carried out at 70° C. to 80° C. for 6 h to 9 h.
[0081]
[0082] The following are specific embodiments
[0083] Example 1
[0084] Step 1. Preparation of intermediate product 3,5-dibromoisobenzofuran-1(3H)-one (Compound 2)
[0085] The synthetic route is:
[0086]
[0087] Add 500mL of carbon tetrachloride and 5-bromoisobenzofuran-1(3H)-one (45.2g, 200.0mmol) to a 1L reaction bottle equipped with a magnetic stirrer, stir and heat to 80℃ and reflux, add azobisisobutyronitrile (2.5g, 14.6mmol) after dissolution, then add N-bromosuccinimide (28.7g, 161.1mmol) in batches, continue stirring for 6h, monitor by TLC, and the reaction is complete. Evaporate the solvent to obtain a yellow oily liquid, which can be used for the next step without further treatment and purification.
[0088] 1 H NMR (400MHz, DMSO-d6) δ7.87(d,J=1.6Hz,1H),7.80(dd,J=8.2,1.7Hz,1H),7.70(d,J=8.1Hz,1H),6.59(s,1H).
[0089] 13 C NMR (100MHz, DMSO-d6) δ168.08,149.90,134.24,128.96,127.45,126.92,126.29,98.14.
[0090] Step 2. Synthesis of 4-bromo-2-formylbenzoic acid (Compound 3)
[0091] The synthetic route is:
[0092]
[0093] Purified water (500 mL) was added to the material from which the solvent was evaporated in the previous step, and the mixture was stirred and refluxed for 2 h. The reaction was completed after monitoring by TLC. The solution was cooled to room temperature, and a white solid precipitated. The solid was filtered and the filter cake was washed with purified water (100 mL × 3). The filter cake was dried to obtain 48.1 g of a white powder. The yield of the two steps was 99.2% in total.
[0094] Step 3. Synthesis of 5-bromo-3-methylisobenzofuran-1(3H)-one (Compound 4)
[0095] The synthetic route is:
[0096]
[0097] The raw material methyl 2-formyl-4-bromobenzoate (49.6g, 204.8mmol) was added to a 1L three-necked flask equipped with a thermometer with a range of -35℃-50℃ and a magnetic stirrer, placed in a low-temperature reaction tank for stirring, vacuumed and replaced with nitrogen at -20℃, anhydrous THF (500mL) was added, and 3mol / L methylmagnesium bromide in ether solution (68.2ml, 204.7mmol) was slowly added. The temperature must not exceed -20℃ during the period. After the addition was completed, the temperature was maintained and vacuumed and replaced with nitrogen three times, and then stirred for 5h. The reaction was monitored by TLC. It was quenched with a saturated aqueous ammonium chloride solution (500ml) and the pH value was adjusted to about 7. The mixed solution was extracted with ethyl acetate, and the organic phases were combined and dried with anhydrous sodium sulfate. The solvent was removed by vacuum drying to obtain 48.4g of a white solid with a yield of 92.1%.
[0098] 1 H NMR (400MHz, DMSO-d6) δ7.98–7.93(m,1H),7.76–7.64(m,2H),5.63(q,J=6.7Hz,1H),1.51(d,J=6.7Hz,3H).
[0099] 13 C NMR (100MHz, DMSO-d6) δ169.40,153.94,132.89,128.89,127.21,126.32,124.77,77.77,20.24.
[0100] ESI-MS: (m / z) 227.15 [M+H] + .
[0101] Step 4. Synthesis of 3-methyl-5-phenoxyisobenzofuran-1(3H)-one (Compound 5)
[0102] The synthetic route is:
[0103]
[0104] 5-Bromo-3-methylisobenzofuran-1(3H)-one (48.4 g, 227.2 mmol), phenol (32.1 g, 340.8 mmol), potassium carbonate (47.1 g, 340.8 mmol), cuprous iodide (4.33 g, 22.7 mmol), and acetylacetone (2.3 mL, 22.7 mmol) were added to a 1 L three-necked flask equipped with a magnetic stirrer, the flask was sealed and evacuated, N2 was replaced, and DMF ( 500mL), stirred and replaced with N2 three times, and kept stirring at 110°C under N2 protection for 10h. The reaction was completed after monitoring by TLC. The reaction was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate (100mL×3). Purified water (2.5L) and ethyl acetate (100mL×3) were added to the filtrate for extraction. The organic phases were combined and dried over anhydrous sodium sulfate. The solvent was evaporated by vacuum concentration. The obtained substance was subjected to column chromatography to obtain 42.5g of a white solid with a yield of 82.5%.
[0105] 1 H NMR (400MHz, DMSO-d6) δ7.75(d,J=8.5Hz,1H),7.48–7.38(m,2H),7.26–7.13(m,2H),7.15–7.02(m,3H),5.56(q,J=6.7Hz,1H),1.46(d,J=6.7Hz,3H).
[0106] 13 C NMR (100MHz, DMSO-d6) δ162.99,155.31,154.73,130.94,127.57,125.51,120.57,119.75,119.20,111.06,77.57,20.50.
[0107] ESI-MS: (m / z) 241.15 [M+H] + .
[0108] Step 5. Synthesis of potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate (Compound 6)
[0109] The synthetic route is:
[0110]
[0111] To a 500 mL eggplant-shaped flask equipped with a magnetic stirrer, 3-methyl-5-phenoxyisobenzofuran-1(3H)-one (33.2 g, 138.0 mmol), isopropanol aqueous solution (i-PrOH:H2O=99:1, 300 mL), and potassium hydroxide (8.52 g, 151.8 mmol) were added. The temperature was raised to 60°C and stirred for 1.5 h. The reaction was completed after TLC monitoring. The reaction was cooled to room temperature and filtered. The filter cake was washed with isopropanol aqueous solution (isopropanol:water=99:1, 50 mL×3) and dried to obtain 40.2 g of a light yellow solid with a yield of 98.2%.
[0112] Step 6. Synthesis of methyl 2-(1-chloroethyl)-4-phenoxybenzoate (Compound 7)
[0113] The synthetic route is:
[0114]
[0115] Potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate (40.16 g, 135.5 mmol) and DMF (400 mL) were added to a 1 L eggplant-shaped flask equipped with a magnetic stirrer. Dimethyl sulfate (18.80 g, 149.1 mmol) was slowly added dropwise to the solution using a constant pressure dropping funnel under an ice-water bath. The mixture was stirred for 1 h. The temperature must not exceed 10 °C during the period. The reaction was complete as monitored by TLC. The temperature was maintained at 0 °C. Triethylamine (41.1 g, 271.0 mmol) was added to the reaction solution. Sulfonyl chloride (19.2 mL, 271.0 mmol) was slowly added dropwise using a constant pressure dropping funnel. The temperature was maintained at 0 °C for 2 h. The reaction was complete as monitored by TLC. Purified water (100 mL) was slowly added dropwise while stirring at this temperature. The mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated in vacuo to remove the solvent to obtain 31.3 g of a colorless oily liquid with a yield of 79.4%.
[0116] Step 7. Synthesis of methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate (Compound 9)
[0117] The synthetic route is:
[0118]
[0119] To a 1L eggplant-shaped flask equipped with a magnetic stirrer, methyl 2-(1-chloroethyl)-4-phenoxybenzoate (31.3 g, 107.7 mmol), methyl p-toluenesulfonylglycine (39.3 g, 161.5 mmol), potassium carbonate (29.8 g, 215.3 mmol), potassium iodide (1.79 g, 10.8 mmol), and DMF (300 mL) were added, the temperature was raised to 50°C, and the mixture was stirred for 4 h. The reaction was completed as monitored by TLC. The reaction was cooled to room temperature, and a methanol solution of sodium methoxide (0.5 mol / L, 300 mL) was added. The mixture was heated to 50°C and stirred for 5 h. The reaction was completed as monitored by TLC. The reaction was cooled to room temperature, and purified water (300 mL) was added. The mixture was stirred under an ice-water bath, and glacial acetic acid was slowly added dropwise to adjust the pH to 7. The mixture was filtered, and the filter cake was washed with acetone. The filter cake was dried to obtain 25.4 g of a white powder solid with a total yield of 76.3% in two steps.
[0120] 1 H NMR (400MHz, DMSO-d6) δ11.41(s,1H),8.21(d,J=9.0Hz,1H),7.51–7.38(m,4H),7.25–7.09(m,3H),3.89(s,3H),2.54(s,3H).
[0121] 13 C NMR(100MHz,DMSO-d6)δ170.91,158.92,155.80,154.55,148.33,132.06,130 .87,126.08,125.16,123.36,122.72,120.07,118.94,112.15,52.89,21.84.
[0122] ESI-MS: (m / z) 310.30 [M+H] +
[0123] Step 8. Synthesis of (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine (roxadustat) The synthetic route is:
[0124]
[0125] To a 500 mL eggplant-shaped flask equipped with a magnetic stirrer, methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate (25.4 g, 82.1 mmol), glycine (18.5 g, 246.4 mmol), 1,8-diazacyclo[5,4,0]undecene (12.3 mL, 82.1 mmol), and acetonitrile (250 mL) were added. The temperature was raised to 80°C and stirred for 6 h. The reaction was completed as monitored by TLC. The reaction was cooled to room temperature and concentrated in vacuo to remove most of the solvent. Purified water (250 mL) and acetic acid (1 g, 17 mmol) were added. Solid precipitated. The mixture was stirred for 0.5 h and filtered. The filter cake was washed with purified water (100 mL×3). The filter cake was transferred to a methanol aqueous solution (methanol:water=1:5, 250 mL), stirred for 0.5 h, filtered, and the filter cake was dried to obtain 28.5 g of a body-colored solid with a yield of 93.2%.
[0126] 1 H NMR (400MHz, DMSO-d6) δ13.25(s,1H),9.05(t,J=6.1Hz,1H),8.23(d,J=9.0Hz,1H),7.55( d,J=2.4Hz,1H),7.55–7.38(m,3H),7.26–7.07(m,3H),3.99(d,J=6.1Hz,2H),2.64(s,3H).
[0127] 13 C NMR(100MHz,DMSO-d6)δ171.23,170.39,158.27,156.01,153.29,147.37,131 .89,130.85,125.72,125.02,123.97,122.89,119.96,112.58,41.14,21.95.
[0128] ESI-MS: (m / z) 353.45 [M+H] + .
[0129] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A method for synthesizing roxadustat, characterized in that: The following steps are involved: (1) mixing 5-bromoisobenzofuran-1(3H)-one as shown in formula I with a brominating agent and a free radical initiator in carbon tetrachloride to carry out a free radical substitution reaction to obtain 3,5-dibromoisobenzofuran-1(3H)-one as shown in formula II, and after concentration, adding water to the obtained concentrated product to carry out a hydrolysis reaction to obtain 4-bromo-2-formylbenzoic acid as shown in formula III; (2) mixing the 4-bromo-2-formylbenzoic acid with methylmagnesium bromide in anhydrous tetrahydrofuran for addition reaction to obtain 5-bromo-3-methylisobenzofuran-1(3H)-one as shown in Formula IV; (3) mixing the 5-bromo-3-methylisobenzofuran-1(3H)-one with phenol, a catalyst, a ligand and an alkali in N,N-dimethylformamide to react to obtain 3-methyl-5-phenoxyisobenzofuran-1(3H)-one as shown in Formula V; (4) subjecting the 3-methyl-5-phenoxyisobenzofuran-1(3H)-one to alkaline hydrolysis in an isopropanol aqueous solution to obtain potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate as shown in Formula VI; (5) mixing the potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate with a methylating agent in an N,N-dimethylformamide solution to carry out a methylation reaction, adding an acid binding agent and a chlorinating agent to the reaction product to continue the reaction, and obtaining methyl 2-(1-chloroethyl)-4-phenoxybenzoate as shown in Formula VII; (6) mixing the methyl 2-(1-chloroethyl)-4-phenoxybenzoate with an acid-binding agent, a catalyst and methyl p-toluenesulfonylglycine in N,N-dimethylformamide to react to obtain methyl 2-(1-((N-(2-methoxy-2-oxoethyl)-4-methylphenyl)sulfonamido)ethyl)-4-phenoxybenzoate as shown in Formula VIII, and adding sodium methoxide-methanol solution to the reaction product to continue the reaction to obtain methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate as shown in Formula IX; (7) reacting the 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester with glycine in an acetonitrile solution under a strong base condition to obtain the rosuvastatin.
2. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (1), the bromination reagent is N-bromosuccinimide, the free radical initiator is azobisisobutyronitrile, the molar ratio of 5-bromoisobenzofuran-1(3H)-one, N-bromosuccinimide and azobisisobutyronitrile is 1:(1.1-2):(0.1-0.2), the temperature of the free radical substitution reaction is 80°C-90°C, the time of the free radical substitution reaction is 6h-7h, the temperature of the hydrolysis reaction is 90°C-100°C, and the time of the hydrolysis reaction is 2h-3h.
3. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (2), the molar ratio of 4-bromo-2-formylbenzoic acid to methylmagnesium bromide is 1:(1 to 1.1), the temperature of the addition reaction is -30°C to -20°C, and the time of the addition reaction is 5h to 6h.
4. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (3), the catalyst is cuprous iodide, the alkali is potassium carbonate, the ligand is acetylacetone, the molar ratio of 5-bromo-3-methylisobenzofuran-1(3H)-one, phenol, potassium carbonate, cuprous iodide and acetylacetone is 1:(1.5-2):(1.5-2):(0.1-0.2):(0.1-0.2), the reaction temperature is 100°C-120°C, and the reaction time is 8h-24h.
5. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (4), the alkaline hydrolysis is carried out in a potassium hydroxide solution, the temperature of the alkaline hydrolysis reaction is 40°C to 60°C, the time of the alkaline hydrolysis reaction is 1h to 4h, and the molar ratio of 3-methyl-5-phenoxyisobenzofuran-1(3H)-one to potassium hydroxide is 1:(1.0 to 1.1).
6. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (5), the methylating agent is dimethyl sulfate, the molar ratio of potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate to dimethyl sulfate is 1:(1.0-1.1), the temperature of the methylation reaction is 0°C to room temperature, the time of the methylation reaction is 1h to 2h, the acid binding agent added after the reaction is completed is triethylamine, the chlorination agent is thionyl chloride, the molar ratio of potassium 2-(1-hydroxyethyl)-4-phenoxybenzoate, triethylamine and thionyl chloride is 1:(1-2):(1-2), the reaction temperature is 0°C to room temperature, and the reaction time is 2h to 4h.
7. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (6), the acid binding agent is potassium carbonate, the catalyst is potassium iodide, the molar ratio of 2-(1-chloroethyl)-4-phenoxybenzoic acid methyl ester, p-toluenesulfonylglycine methyl ester, potassium carbonate, and potassium iodide is 1.0:(1.5-2.0):2.0:0.1, the reaction temperature is 50°C-60°C, the reaction time is 2h-8h, and after the reaction is completed, sodium methoxide-methanol solution is added and the reaction is continued at 50°C-70°C for 4h-7h.
8. The method for synthesizing roxadustat according to claim 1, characterized in that: In step (7), the base is 1,8-diazacyclo[5,4,0]undecene-7; the molar ratio of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid methyl ester, glycine, and 1,8-diazacyclo[5,4,0]undecene is 1:(2-4):(2-3), the reaction temperature is 70°C to 80°C, and the reaction time is 6h to 9h.
Citation Information
Cited By
An improved process for highly pure roxadustat
WO2026142523A3
